Professor at Karolinska Institutet since 1998, firstly of Neurophysiology and, as of 2007, of Integrative Medicine as well as leading research activities at the Osher Center for Integrative Medicine.
Deputy Vice-Chancellor for Future Healthcare and then Deputy Vice-Chancellor for Development, 2014-2017.
Docent (Associate Professor) 1984 at Lund University in experimental neurological research. Docent 1992 at Karolinska Institutet in Clinical Neurophysiology.
- 1998- Director of Karolinska MR Center
- 2012- PI at National MEG center KI
- 2012- Board member of ICHOM Foundation
- 2013- Chairman of the board for Swedish Research Council for health, working life and welfare (Forte)
Former representative posts
- 1996-2002 Coordinator for Karolinska PET
- 2001-2004 Deputy Head of the Department of Clinical Neuroscience and Head of the Department of Clinical Neuroscience 2004-2010
- 2002-2006 Chairman of the Board for World Childhood Foundation.
- 2010-2013 Dean of Research, Karolinska Institutet.
- 2013-2017 Chairman of the board for Swelife – a strategic initiative within life science
- 2014-2017 Deputy Vice-Chancellor for questions about future healthcare and external cooperations
- Medical Degree at Lund University 1984
- Doctor of Medical Science at Lund University in 1982 in experimental neurological research.
Our research arena in cognitive neuroscience consists of several groups. We host the Osher Center for Integrative Medicine, the MR Research Center which focuses on structural and functional imaging of the human brain and also the national MEG infrastructure. The accent of my research is placed on pain and emotional modulation in the forebrain. The methodological span extends from the gene to behaviour.
The Osher Center for Integrative Medicine whose purpose is to enhance knowledge through scientific methods of those mechanisms that are utilised in patient treatment both in ordinary healthcare activities and within alternative/complementary medicine.
At the Osher Center it has been demonstrated that many complementary therapies rest on placebo mechanisms that can be demonstrated both in the nervous system and the immune system in interaction. One good example is that regulating pain in fibromyalgia has reduced capacity and that the reduction co-varies with a diminished activity in the brain’s system for top-down pain modulation.
Academic honours, awards and prizes